Aadi Bioscience annual meeting elects directors, says-on-pay passes, auditor ratified

Whitehawk Therapeutics, Inc.

Elected three Class III directors: Aghazadeh (8.36M for), Maroun (9.87M), Reeve (9.87M).
Advisory say-on-pay approved: 9.74M for, 0.28M against, 17K abstentions.
Shareholders voted for annual say-on-pay frequency (9.83M for 1 year); next vote by 2029.
Ratified BDO USA as auditor for FY2023: 13.85M for, 73K against, 3K abstentions.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Whitehawk Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

For Against Abstentions 13,850,448 72,970 2,786

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory (non-binding) basis, the frequency of future Say-on-Pay Votes. at the 2023-06-14 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

1 Year 2 Years 3 Years Abstentions Broker Non-Votes 9,832,520 2,546 75,231 120,267 N/A

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory basis, the compensation of the named executive officers identified in the 2022 Summary Compensation Table in the “Executive Compensation” section of the Proxy Statement. at the 2023-06-14 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

For Against Abstentions Broker Non-Votes 9,738,074 275,337 17,153 3,895,640

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Whitehawk Therapeutics, Inc. shareholders approved Election of three Class III directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors have been elected or qualified. at the 2023-06-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

Broker Director For Withheld Non-Votes Behzad Aghazadeh, Ph.D. 8,361,137 1,669,427 3,895,640 Richard Maroun 9,872,401 158,163 3,895,640 Emma Reeve 9,871,998 158,566 3,895,640

View on SEC.gov

288 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-022421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.